Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes.
hypertriglyceridemia
pemafibrate
triglyceride
type 2 diabetes
Journal
JMA journal
ISSN: 2433-3298
Titre abrégé: JMA J
Pays: Japan
ID NLM: 101769797
Informations de publication
Date de publication:
15 Apr 2021
15 Apr 2021
Historique:
received:
27
11
2020
accepted:
12
02
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
18
5
2021
Statut:
ppublish
Résumé
Pemafibrate is a potent selective peroxisome proliferator-activated receptor α (PPARα) modulator that may be safer than conventional PPARα agonists in the treatment of dyslipidemia. This study was designed to investigate the efficacy of low-dose pemafibrate (0.1 mg/day) therapy for hypertriglyceridemia in 31 patients with type 2 diabetes and high triglyceride (TG) levels at the Manda Memorial Hospital. TG, remnant lipoprotein cholesterol (RLP-C), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein (Apo) AI, Apo AII, Apo B, Apo CII, Apo CIII, and Apo E levels were evaluated. Liver, kidney, and muscle toxicity tests were also performed. Pemafibrate (0.1 mg) was administered once daily. This treatment significantly decreased TG, RLP-C, Apo CII, Apo CIII, and Apo E levels while significantly increasing HDL-C, Apo AI, and Apo AII levels. No significant changes were observed in LDL-C and Apo B levels. There were no significant liver-, kidney-, or muscle-related adverse events. The results of this study show that low-dose pemafibrate administration improves the lipid profile in Japanese patients with hypertriglyceridemia and type 2 diabetes.
Identifiants
pubmed: 33997447
doi: 10.31662/jmaj.2020-0104
pmc: PMC8118964
doi:
Types de publication
Journal Article
Langues
eng
Pagination
135-140Informations de copyright
Copyright © Japan Medical Association.
Déclaration de conflit d'intérêts
Taneda S. received honoraria for lectures from Takeda Pharmaceutical Co., Ltd., and Novo Nordisk Pharma.
Références
Lancet. 2015 Apr 11;385(9976):1397-405
pubmed: 25579834
J Clin Lipidol. 2018 Jan - Feb;12(1):173-184
pubmed: 29203092
Diabetes Care. 2018 Mar;41(3):538-546
pubmed: 29298800
J Clin Invest. 1985 Feb;75(2):710-21
pubmed: 3973025
J Am Coll Cardiol. 2015 Jun 2;65(21):2267-75
pubmed: 26022813
J Atheroscler Thromb. 2019 May 1;26(5):389-402
pubmed: 30930344
J Clin Invest. 2016 Aug 1;126(8):2855-66
pubmed: 27400128
Expert Rev Cardiovasc Ther. 2017 Dec;15(12):913-921
pubmed: 29183206
Diabetes Obes Metab. 2019 Jul;21(7):1737-1744
pubmed: 30830727
Diabetes Obes Metab. 2011 Apr;13(4):313-25
pubmed: 21205114
Circulation. 2009 Jun 23;119(24):3078-84
pubmed: 19506114
Atherosclerosis. 2016 Jun;249:36-43
pubmed: 27062408
J Atheroscler Thromb. 2018 Jun 1;25(6):521-538
pubmed: 29628483
Clin Hemorheol Microcirc. 1999;21(2):79-85
pubmed: 10599590
Atherosclerosis. 2017 Dec;267:49-60
pubmed: 29100061
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Cardiovasc Diabetol. 2019 Mar 21;18(1):38
pubmed: 30898163
Curr Atheroscler Rep. 2016 May;18(5):25
pubmed: 27005803
Cardiovasc Diabetol. 2017 Oct 4;16(1):124
pubmed: 28978316
J Clin Med Res. 2019 Oct;11(10):690-695
pubmed: 31636783